Oral etoposide as a single agent in childhood and young adult cancer in EnglandCitation formats

  • External authors:
  • Jess Fraser
  • Fahmina Fardus-Reid
  • Lucy Irvine
  • Lucy Elliss-Brookes
  • Lorna Fern
  • Alison L Cameron
  • Kathy Pritchard-Jones
  • Richard G Feltbower
  • Jon Shelton
  • Charles Stiller

Standard

Oral etoposide as a single agent in childhood and young adult cancer in England : Still a poorly evaluated palliative treatment. / Fraser, Jess; Fardus-Reid, Fahmina; Irvine, Lucy; Elliss-Brookes, Lucy; Fern, Lorna; Cameron, Alison L; Pritchard-Jones, Kathy; Feltbower, Richard G; Shelton, Jon; Stiller, Charles; McCabe, Martin G.

In: Pediatric Blood & Cancer, 23.09.2021, p. e29204.

Research output: Contribution to journalArticlepeer-review

Harvard

Fraser, J, Fardus-Reid, F, Irvine, L, Elliss-Brookes, L, Fern, L, Cameron, AL, Pritchard-Jones, K, Feltbower, RG, Shelton, J, Stiller, C & McCabe, MG 2021, 'Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment', Pediatric Blood & Cancer, pp. e29204. https://doi.org/10.1002/pbc.29204

APA

Fraser, J., Fardus-Reid, F., Irvine, L., Elliss-Brookes, L., Fern, L., Cameron, A. L., Pritchard-Jones, K., Feltbower, R. G., Shelton, J., Stiller, C., & McCabe, M. G. (2021). Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment. Pediatric Blood & Cancer, e29204. https://doi.org/10.1002/pbc.29204

Vancouver

Fraser J, Fardus-Reid F, Irvine L, Elliss-Brookes L, Fern L, Cameron AL et al. Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment. Pediatric Blood & Cancer. 2021 Sep 23;e29204. https://doi.org/10.1002/pbc.29204

Author

Fraser, Jess ; Fardus-Reid, Fahmina ; Irvine, Lucy ; Elliss-Brookes, Lucy ; Fern, Lorna ; Cameron, Alison L ; Pritchard-Jones, Kathy ; Feltbower, Richard G ; Shelton, Jon ; Stiller, Charles ; McCabe, Martin G. / Oral etoposide as a single agent in childhood and young adult cancer in England : Still a poorly evaluated palliative treatment. In: Pediatric Blood & Cancer. 2021 ; pp. e29204.

Bibtex

@article{b79269194c7249709feb8a80dd0a2d4f,
title = "Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment",
abstract = "BACKGROUND: Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population-level data.METHODS: Patients aged under 25 years at cancer diagnosis (1995-2017) with a treatment record of single-agent oral etoposide in the Systemic AntiCancer Dataset (SACT, 2012-2018) were identified, linked to national cancer registry data using NHS number and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours combined and by tumour group. A Cox model was applied accounting for age, sex, tumour type, prior and subsequent chemotherapy.RESULTS: Total 115 patients were identified during the study period. Mean age was 11.8 years at cancer diagnosis and 15.5 years at treatment with oral etoposide. Median OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years. Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one cycle (range one to nine) of etoposide was delivered. OS correlated significantly with tumour type and prior chemotherapy, but not with other variables.CONCLUSIONS: This report is the largest series to date of oral etoposide use in childhood and young adult cancer. Most patients treated in this real world setting died quickly. Despite decades of use, there are still no robust data demonstrating a clear benefit of oral etoposide for survival.",
author = "Jess Fraser and Fahmina Fardus-Reid and Lucy Irvine and Lucy Elliss-Brookes and Lorna Fern and Cameron, {Alison L} and Kathy Pritchard-Jones and Feltbower, {Richard G} and Jon Shelton and Charles Stiller and McCabe, {Martin G}",
note = "{\textcopyright} 2021 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.",
year = "2021",
month = sep,
day = "23",
doi = "10.1002/pbc.29204",
language = "English",
pages = "e29204",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley & Sons Ltd",

}

RIS

TY - JOUR

T1 - Oral etoposide as a single agent in childhood and young adult cancer in England

T2 - Still a poorly evaluated palliative treatment

AU - Fraser, Jess

AU - Fardus-Reid, Fahmina

AU - Irvine, Lucy

AU - Elliss-Brookes, Lucy

AU - Fern, Lorna

AU - Cameron, Alison L

AU - Pritchard-Jones, Kathy

AU - Feltbower, Richard G

AU - Shelton, Jon

AU - Stiller, Charles

AU - McCabe, Martin G

N1 - © 2021 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

PY - 2021/9/23

Y1 - 2021/9/23

N2 - BACKGROUND: Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population-level data.METHODS: Patients aged under 25 years at cancer diagnosis (1995-2017) with a treatment record of single-agent oral etoposide in the Systemic AntiCancer Dataset (SACT, 2012-2018) were identified, linked to national cancer registry data using NHS number and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours combined and by tumour group. A Cox model was applied accounting for age, sex, tumour type, prior and subsequent chemotherapy.RESULTS: Total 115 patients were identified during the study period. Mean age was 11.8 years at cancer diagnosis and 15.5 years at treatment with oral etoposide. Median OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years. Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one cycle (range one to nine) of etoposide was delivered. OS correlated significantly with tumour type and prior chemotherapy, but not with other variables.CONCLUSIONS: This report is the largest series to date of oral etoposide use in childhood and young adult cancer. Most patients treated in this real world setting died quickly. Despite decades of use, there are still no robust data demonstrating a clear benefit of oral etoposide for survival.

AB - BACKGROUND: Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population-level data.METHODS: Patients aged under 25 years at cancer diagnosis (1995-2017) with a treatment record of single-agent oral etoposide in the Systemic AntiCancer Dataset (SACT, 2012-2018) were identified, linked to national cancer registry data using NHS number and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours combined and by tumour group. A Cox model was applied accounting for age, sex, tumour type, prior and subsequent chemotherapy.RESULTS: Total 115 patients were identified during the study period. Mean age was 11.8 years at cancer diagnosis and 15.5 years at treatment with oral etoposide. Median OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years. Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one cycle (range one to nine) of etoposide was delivered. OS correlated significantly with tumour type and prior chemotherapy, but not with other variables.CONCLUSIONS: This report is the largest series to date of oral etoposide use in childhood and young adult cancer. Most patients treated in this real world setting died quickly. Despite decades of use, there are still no robust data demonstrating a clear benefit of oral etoposide for survival.

U2 - 10.1002/pbc.29204

DO - 10.1002/pbc.29204

M3 - Article

C2 - 34227732

SP - e29204

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -